AnaptysBio Inc (ANAB) - Total Assets
Based on the latest financial reports, AnaptysBio Inc (ANAB) holds total assets worth $329.68 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AnaptysBio Inc - Total Assets Trend (2013–2025)
This chart illustrates how AnaptysBio Inc's total assets have evolved over time, based on quarterly financial data. Also see AnaptysBio Inc market capitalisation for the company's overall valuation and market capitalisation.
AnaptysBio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
AnaptysBio Inc's total assets of $329.68 Million consist of 96.1% current assets and 3.9% non-current assets. Review AnaptysBio Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.4% |
| Accounts Receivable | $33.85 Million | 9.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how AnaptysBio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of AnaptysBio Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AnaptysBio Inc's current assets represent 96.1% of total assets in 2025, an increase from 78.0% in 2013.
- Cash Position: Cash and equivalents constituted 65.4% of total assets in 2025, down from 71.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 9.3% of total assets.
AnaptysBio Inc Competitors by Total Assets
Key competitors of AnaptysBio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
AnaptysBio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.58 | 8.25 | 19.31 |
| Quick Ratio | 7.58 | 8.25 | 19.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $274.41 Million | $319.07 Million | $377.44 Million |
AnaptysBio Inc - Advanced Valuation Insights
This section examines the relationship between AnaptysBio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 131.61 |
| Latest Market Cap to Assets Ratio | 4.44 |
| Asset Growth Rate (YoY) | -24.7% |
| Total Assets | $364.39 Million |
| Market Capitalization | $1.62 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values AnaptysBio Inc's assets at a significant premium (4.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: AnaptysBio Inc's assets decreased by 24.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AnaptysBio Inc (2013–2025)
The table below shows the annual total assets of AnaptysBio Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $364.39 Million | -24.69% |
| 2024-12-31 | $483.83 Million | +6.95% |
| 2023-12-31 | $452.39 Million | -25.88% |
| 2022-12-31 | $610.38 Million | -5.08% |
| 2021-12-31 | $643.07 Million | +54.38% |
| 2020-12-31 | $416.55 Million | -4.28% |
| 2019-12-31 | $435.20 Million | -14.50% |
| 2018-12-31 | $509.00 Million | +54.54% |
| 2017-12-31 | $329.36 Million | +429.69% |
| 2016-12-31 | $62.18 Million | +10.48% |
| 2015-12-31 | $56.28 Million | +124.54% |
| 2014-12-31 | $25.07 Million | +540.39% |
| 2013-12-31 | $3.91 Million | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more